All News
Morand et al Tyk2i deucravacitinib in SLE. 48-week phase 2 RCT. SRI(4) PBO: 34.4%; DEUC 3 mg BID: 58.2%, P =0.0006; DEUC 6 mg BID: 49.5%, P =0.021; DEUC 12 mg QD: 44.9%, P =0.078. BICLA, LLDAS, CLASI-50, active joint count also+ @RheumNow #EULAR2022 LB0004 https://t.co/MBPc9xQFvG https://t.co/n3GUwl0RtD
Links:
Richard Conway RichardPAConway ( View Tweet)
BE OPTIMAL Phase 3 RCT
Bimekizumab dual IL17A & F inhibitor in bionaive PsA
⭐️ACR50 wk 16 43.9% vs 10% PBO
⭐️PASI 90 wk 16 61% vs. 3% PBO
⭐️separation from wk 4
Safety: fungal injections BKZ > ADA
@RheumNow
LB0001 #EULAR2022 https://t.co/7ZwV1XDSNb
Aurelie Najm AurelieRheumo ( View Tweet)
PAISLEY LB004
@EricFMorand on deucravacitinib phase 2 for SLE
⭐️Meets primary endpt: SRI(4)
⭐️Secondary endpts: BICLA, LLD, CLASI, jt count, biomarkers improved
⭐️Safety data wo VTE, CVD events
Earlier at #EULAR2022, BRAVE trial phase 3 baricitinib: No benefit in SLE
@RheumNow https://t.co/3YpPSJcenF
Eric Dein ericdeinmd ( View Tweet)
Wetterslev et al showed that almost all of 108 axSpA patients in clinical remission flared during tapering,47% flared at 2/3 to ½ dose and 53% at 1/3 to discontinuation. Higher baseline physician global score was an independent predictor of flare #EULAR2022 @RheumNow POS0298 https://t.co/RELuiB3Enl
Dr. Antoni Chan synovialjoints ( View Tweet)
PAISLEY study Phase 2 RCT
Deucravacitinib in SLE meets primary endpoint wk 32
Results for dose 3mg BID:
*SRI(4) response 58.2% vs.
PBO 34%
*LLDAS 36%
*CLASI 70%
*⬇️ SJC
No new safety signal
Now waiting for Phase 3 👀
@RheumNow LB0004 #EULAR2022 #Lupus https://t.co/2KYSvfq4h7
Aurelie Najm AurelieRheumo ( View Tweet)
Dr Coates @DrLauraCoates et al. Domains contributing to MDA achievement in guselkumab treated PsA. Physican assessed improved faster than patient assessed. Age, fatigue, BMI, baseline domain score determinants @RheumNow #EULAR2022 POS1067 https://t.co/vPsmeyPjzG
Richard Conway RichardPAConway ( View Tweet)
Talking about tapering studies in inflammatory arthritis, but true throughout all of rheumatology:
Not all flares are equal.
This area is full of nuance, we need to think more closely about how we study them.
#EULAR2022 @RheumNow https://t.co/tzqqNZv5Ct
David Liew drdavidliew ( View Tweet)
#POS1112 #EULAR2022 A crossover RCT assessed effect of weight- and non-weight bearing exercises on type 2 collagen in knee #osteoarthritis. Small rise in collagen turnover markers initially for 24hrs. Gradual rise later on was contributed to cardiovascular influence @RheumNow https://t.co/AOxdFNihPR
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Shall we include US findings in CASPAR criteria? ⚡️
Adding US tenosynovitis
and/or enthesitis
- improves Specificity 91% vs. 68%
-while maintaining sensitivity 92% vs. 96%
#EULAR2022 @RheumNow POS0315 https://t.co/kuxPpVEQng
Aurelie Najm AurelieRheumo ( View Tweet)
Dr Nash @drpnash Baseline determinants of pain response in IL23i guselkumab. Gus improved pain by week 2. Higher baseline pain, lower fatigue, lower TJC + predictors, NSAID use - predictor @RheumNow #EULAR2022 POS1070 https://t.co/4aNz9IQySj
Richard Conway RichardPAConway ( View Tweet)
The potential for patients to benefit from digital health technologies in rheumatology is multifaceted, upside might be enormous.
There's so much space for us all, but there are factors in many domains where it can all go wrong.
We need to raise standards.
#EULAR2022 @RheumNow https://t.co/TozfK1Qs16
David Liew drdavidliew ( View Tweet)
High markers at baseline of IL23 pathway better predict ACR20 response to #deucracitinib in #PsA #psoriatic arthritis. Analysis of RCT @eular_org @RheumNow #POS0005 Good proof of concept of TYK2 efficacy https://t.co/yyH5niUEEU
Janet Pope Janetbirdope ( View Tweet)
Therkildsen et al Ocular manifestations GCA in Denmark. Quite low proportion at 7%. Most occur around time diagnosis, with 1/3 pre-diagnosis. Aspirin not assoc reduced risk. @RheumNow #EULAR2022 POS0791 https://t.co/YgailfJ6fI
Richard Conway RichardPAConway ( View Tweet)
New in AS. Upadacitinib 15mg od was significantly more effective than placebo over 14 weeks in AS bDMARD-IR (ASAS40 45% vs 18% and the onset of effect seen by week 4), no new safety risks identified in the SELECT-AXIS 2 study by Van de Heijde et al #EULAR2022 @RheumNow POS0306 https://t.co/LCQBf38GWe
Dr. Antoni Chan synovialjoints ( View Tweet)
CorEvitas PsA Registry (1000+ pts)
Analysis of biologics prescription according to disease domains
No real surprise to see that IL-17i were prescribed more frequently in pts w/ PsO BSA>10% at BL
Overall first line TNFi 40% > IL-17i 14%
POS0309 @RheumNow #EULAR2022 https://t.co/dkLxl8d6ug
Aurelie Najm AurelieRheumo ( View Tweet)
Everything's better with MTX
Controlled RA on b/tsDMARDs: can we taper MTX?
maintaining remission pooled OR 0.81 (0.68-0.97)
Unless I'm reading it wrong:
it's true many will be fine, but
keeping MTX adds benefit (even in short term, before ADAb)
POS0286 #EULAR2022 @RheumNow https://t.co/ZlwXHgACWd
David Liew drdavidliew ( View Tweet)
SELECT-AXIS 1 trial of upadacitinib in active #AS with an inadequate resp to prior biologic - pivotal phase 2/3 RCT of 420 AS pts (Dz dur 7.7 yrs; 83% B27+) showed better ASAS40 at wk 14 w/ UPA vs PBO (45% vs 18%; P<0.0001) #EULAR2022 POS0306 https://t.co/6ZBEvjRjqc https://t.co/GL0vlB34mE
Links:
Dr. John Cush RheumNow ( View Tweet)
Cantoni et al. Maladaptive trained immunity in GCA. Aberrant activation of trained immunity programs in myelomonocytic cells leads to sustained and enhanced inflammatory activation and increased expression inflammatory cytokines (esp IL6) @RheumNow #EULAR2022 POS0492 https://t.co/A8t9gV1O3d
Richard Conway RichardPAConway ( View Tweet)
Charles-Schoeman et al. ORAL Surveillance, post-hoc analysis of risk factor combinations. 65+ ever smokers appear at particular risk @RheumNow #EULAR2022 POS0674 https://t.co/UyTOITBTX9
Richard Conway RichardPAConway ( View Tweet)
If rheumatoid arthritis comes and goes before a rheumatologist lays their hands on it, is it really RA?
We're born skeptical on this. Ronald van Vollenhoven poses questions on what it means for studying drug-free remission in established RA disease #EULAR2022 @RheumNow https://t.co/9GJoqYtVBP
David Liew drdavidliew ( View Tweet)